Showing 1 - 11 results of 11 for search 'Olle Stål', query time: 0.04s Refine Results
  1. 1
    Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer.

    Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer. by Susann Busch, Lisa Rydén, Olle Stål, Karin Jirström, Göran Landberg

    Published 2012-01-01
    Get full text
    Article
  2. 2
    17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer.

    17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer. by Tove Sivik, Cecilia Gunnarsson, Tommy Fornander, Bo Nordenskjöld, Lambert Skoog, Olle Stål, Agneta Jansson

    Published 2012-01-01
    Get full text
    Article
  3. 3
    Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer

    Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer by Brock Schroeder, Yi Zhang, Olle Stål, Tommy Fornander, Adam Brufsky, Dennis C. Sgroi, Catherine A. Schnabel

    Published 2017-08-01
    Get full text
    Article
  4. 4
    Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis.

    Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis. by Elin Karlsson, Ivana Magić, Josefine Bostner, Christine Dyrager, Fredrik Lysholm, Anna-Lotta Hallbeck, Olle Stål, Patrik Lundström

    Published 2015-01-01
    Get full text
    Article
  5. 5
    Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer

    Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer by Karoline Berger, Sara Rhost, Svanheiður Rafnsdóttir, Éamon Hughes, Ylva Magnusson, Maria Ekholm, Olle Stål, Lisa Rydén, Göran Landberg

    Published 2021-02-01
    Get full text
    Article
  6. 6
    The role of microRNA-200 in progression of human colorectal and breast cancer.

    The role of microRNA-200 in progression of human colorectal and breast cancer. by Linda Bojmar, Elin Karlsson, Sander Ellegård, Hans Olsson, Bergthor Björnsson, Olof Hallböök, Marie Larsson, Olle Stål, Per Sandström

    Published 2013-01-01
    Get full text
    Article
  7. 7
    PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients

    PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients by Christine Lundgren, Pär-Ola Bendahl, Sarah E. Church, Maria Ekholm, Mårten Fernö, Carina Forsare, Ute Krüger, Bo Nordenskjöld, Olle Stål, Lisa Rydén

    Published 2022-05-01
    Get full text
    Article
  8. 8
    Long-term follow-up of early stage HER2-positive breast cancer patients treated with trastuzumab: A population-based real world multicenter cohort study

    Long-term follow-up of early stage HER2-positive breast cancer patients treated with trastuzumab: A population-based real world multicenter cohort study by Sander Ellegård, Sander Ellegård, Kristina Engvall, Kristina Engvall, Mustafa Asowed, Anna-Lotta Hallbeck, Anna-Lotta Hallbeck, Nils Elander, Nils Elander, Olle Stål

    Published 2022-08-01
    Get full text
    Article
  9. 9
    Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial

    Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial by Christine Lundgren, Julia Tutzauer, Sarah E. Church, Olle Stål, Maria Ekholm, Carina Forsare, Bo Nordenskjöld, Mårten Fernö, Pär-Ola Bendahl, Lisa Rydén

    Published 2023-09-01
    Get full text
    Article
  10. 10
    Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy

    Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy by Anna Nordenskjöld, Helena Fohlin, Johan Rosell, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per Malmström, Lisa Rydén, Arne Wallgren, Olle Stål, Bo Nordenskjöld

    Published 2023-10-01
    Get full text
    Article
  11. 11
    MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

    MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit by Sanne Løkkegaard, Daniel Elias, Carla L. Alves, Martin V. Bennetzen, Anne-Vibeke Lænkholm, Martin Bak, Morten F. Gjerstorff, Lene E. Johansen, Henriette Vever, Christina Bjerre, Tove Kirkegaard, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Linda S. Lindström, Laura J. Esserman, Anne E. Lykkesfeldt, Jens S. Andersen, Rikke Leth-Larsen, Henrik J. Ditzel

    Published 2021-01-01
    Get full text
    Article

Search Tools: